NCT05227482 (DOSEY90) is a Phase 2 clinical trial of Personalized dosimetry approach in HCC, sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna.

Who is sponsoring NCT05227482?

NCT05227482 is sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna.

What drugs are being tested in NCT05227482?

Interventions in NCT05227482: Personalized dosimetry approach, Standard dosimetry approach.

Is NCT05227482 still recruiting?

NCT05227482 is currently status unknown. Last updated 7 February 2022.

Last reviewed 2022-02-07 · How we verify

NCT05227482: DOSEY90

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Accurate Dosimetry and Biomarkers Improve Survival in HCC Patients Treated With Resin 90 Yttrium (90Y)-Microspheres

Status unknown Phase 2 Last updated 7 February 2022

What this trial tests

Phase 2 trial testing Personalized dosimetry approach in HCC in 150 participants. Status unknown.

Timeline

10 April 2018

Primary endpoint
31 December 2023

31 December 2023

Quick facts

Lead sponsor	IRCCS Azienda Ospedaliero-Universitaria di Bologna
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	150
Start date	10 April 2018
Primary completion	31 December 2023
Estimated completion	31 December 2023
Sites	1 location across Italy

Drugs / interventions tested

Personalized dosimetry approach
Standard dosimetry approach

Conditions studied

HCC — all drugs for HCC →

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna — full company profile →

Who can join

18 and older, any sex, with HCC. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial involves patients with hepatocellular carcinoma (HCC) diagnosis treated with transarterial radioembolization (TARE) with resin microspheres loaded with 90Y. Patients will be divided in two groups based on prescription method to calculate the therapeutic radionuclide activity to be injected. In arm A, standard dosimetric approach such as Body Surface Area (BSA) method and Medical Internal Radiation Dosimetry (MIRD) monocompartmental method will be used. In arm B, novel voxel-based dosimetry, based on pre-treatment simulation with 99m-Technetium (99mTc)-Macro Aggregated Albumin (MAA) injection and SPECT/CT image acquisition, will be used. The primary outcome will be the overall survival of patients included in arm A and arm B. Secondary outcomes will be adverse events, tumor response, biomarkers assessed from blood samples prior and after the treatment and voxel-based dosimetry obtained from post-treatment PET/CT images acquisitions.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Overview of Ongoing Clinical Trials on Radioembolization.
Fabritius MP, Ricke J. · · 2022 · cited 7× · PMID 36184696 · DOI 10.1007/s00270-022-03270-4
Review of brachytherapy clinical trials: a cross-sectional analysis of ClinicalTrials.gov.
Chen D, Parsa R, Chauhan K, Lukovic J, et al · · 2024 · cited 2× · PMID 38351013 · DOI 10.1186/s13014-024-02415-8

Verify or expand the search:

Other recruiting trials for HCC

Currently open trials in the same condition.

NCT07145801 — Y-90 Treatment Response Using Transarterial Radioembolization · Phase 2 · recruiting
NCT07300488 — Efficacy and Safety of Pracytarabine Versus Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma · Phase 2, PHASE3 · active not recruiting
NCT07334483 — A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC · Phase 2 · recruiting
NCT07099274 — Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy f · Phase 2 · recruiting
NCT06717919 — HOPE Against Cancer Recurrence in HCC · Phase 4 · recruiting

Other IRCCS Azienda Ospedaliero-Universitaria di Bologna trials

Trials by the same sponsor.

NCT06718049 — Role of Interleukin 18 (IL-18) and Interleukin 18 Binding Protein (IL-18BP) in the Diagnostic Work-up of Systemic Juveni · not yet recruiting
NCT07490392 — Growth and Endocrinological Outcomes in Patients Who Underwent or Did Not Undergo Haematopoietic Stem Cell Transplantati · not yet recruiting
NCT07483853 — Reliability and Validation of the WB-MRI Radiological Score in CRMO · recruiting
NCT07479121 — These Studies Assess Surgeons' Physical and Ergonomic Workloads. Study 1 Compares Laparoscopic vs. Hugo RAS Robotic Appr · NA · not yet recruiting
NCT07471009 — Development of Patient Derived Xenografts (PDXs) and Analysis of Tyrosine Kinase Receptor Expression in Patients With Sq · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05227482 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by IRCCS Azienda Ospedaliero-Universitaria di Bologna
Last refreshed: 7 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05227482.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing